Long Non-coding RNAs act as Prognostic Biomarkers in Breast and Gynecologic Cancers

Fan Zhao  
Zhejiang University School of Medicine  
Huiqi Chen  
Zhejiang University School of Medicine  
Kelie Chen  
Zhejiang University School of Medicine  
Shengchao Wang  
Zhejiang University School of Medicine  
Dexin Yang  
Zhejiang University School of Medicine  
Honghe Zhang  
Zhejiang University School of Medicine  
Weiguo Lu  
Zhejiang University School of Medicine  
Dajing Xia  
Zhejiang University School of Medicine  
Yihua Wu (✉️ georgewu@zju.edu.cn)  
Zhejiang University, Hangzhou

Research article

Keywords: lncRNAs, Breast cancer, Gynecologic cancer, Prognosis, Biomarkers

DOI: https://doi.org/10.21203/rs.3.rs-132435/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

It is well-known that long non-coding RNAs (lncRNAs) play essential roles in cancer development and progression. This study aimed to assess the potential prognostic value of specific lncRNAs in breast and gynecologic cancers.

Methods

PubMed, EMBASE, Cochrane library and TCGA databases were systematically searched from inception to January, 2019, and identified according to eligibility criteria. A random-effects model was adopted to calculate combined hazard ratios to explore the association between specific lncRNA expression level and survival in breast and gynecologic cancers. Subgroup and publication bias analyses were also conducted.

Results

111 studies encompassing nearly 20000 participants and 25 lncRNAs were included in the current study. Of the listed lncRNAs, we identified 3 lncRNAs significantly associated with both overall survival (OS) and disease-free survival (DFS) in breast and gynecologic cancers, indicating that they might act as promising prognostic biomarkers in clinical applications. Specifically, HOTAIR and PVT1 had a negative impact on survival outcome, while GAS5 was associated with better prognosis. Further subgroup analyses identified HOTAIR as a biomarker for the poor survival whether in an Asian population or in European and American populations and GAS5 as a biomarker for the relatively good prognosis of both breast and gynecologic cancers.

Conclusions

We here highlight that abnormal expression of 3 lncRNAs, including HOTAIR, GAS5, PVT1 might significantly affect the survival of breast and gynecologic cancer patients and serve as novel prognostic biomarkers for breast and gynecologic cancers.

Introduction

Breast and gynecologic cancers, including breast cancer, ovarian cancer, endometrial cancer and cervical cancer, are the major malignant tumors in women worldwide and seriously endanger the health of women, which account for nearly 40% of cancer risk and 30% of cancer mortality for women [1]. As estrogen associated tumors, it is widely accepted that breast cancer and gynecologic cancers share several similar risk factors and genetic characteristics [2, 3]. Besides, the prognosis of breast and gynecologic cancers is still not optimistic owing to the distinctive properties of easy metastasis [4, 5].

Recent genome sequencing studies have shown that the human genome consists of less than 2% protein-coding genes, and more than 90% of genome is transcribed into non-coding RNAs [6, 7]. Long non-coding RNAs (lncRNAs) are defined as transcripts greater than 200 nucleotides in length without protein encoding.
potential [8]. Although lncRNAs are incapable of encoding proteins, it can regulate gene expression at various levels, such as transcriptional regulation, post-transcriptional regulation and epigenetic mode [9, 10]. Nowadays, an increasing number of lncRNAs have been identified due to the development of high-throughput sequencing.

Interestingly, plenty of lncRNAs were only expressed in differentiated tissues or specific cancer types [11]. Previous studies demonstrated the participants of lncRNAs in different types of human cancers with both oncogenic and tumor repressive effects. And their enrichment, conserved sequences, and altered expression have been observed in breast and ovarian cancers [12]. It was proposed that lncRNAs could target chromatin modification complexes or RNA binding proteins to alter gene expressing programs which exhibited distinct gene expression patterns in primary tumors and metastases [13]. In addition, available studies have recognized the considerable role of lncRNAs in various stages of carcinogenesis and metastasis [14]. And metastasis was the most important biological behavior of tumor development and progression and closely related to cancer prognosis. Therefore, specific lncRNAs might be explored as potential prognostic biomarkers for breast and gynecologic cancers.

Several studies have evaluated the association between tissue lncRNA expression and breast and gynecologic cancers but the results did not reach a consensus with each other. For instance, Gupta et al. demonstrated that HOTAIR was increased in expression in primary tumors and metastases in breast cancer [15]. However, Lu et al. found that HOTAIR globally induced repressive chromatin status by promoting the formation of H3K27me3, suggesting that HOTAIR might act as a tumor suppressor under certain conditions [16]. Zhang et al. proposed that low expression of MEG3 was likely to be related to promoter hypermethylation in cervical cancer [17]. Cao et al. reported that CCAT1 was upregulated in epithelial ovarian cancer (EOC) tissues, and significantly associated with FIGO stage, histological grade and poorer survival of EOC patients [18]. Besides, it was shown that MALAT1 was downregulated in breast cancer tissue, and knockdown of MALAT1 in breast cancer cell lines induced epithelial-mesenchymal transition (EMT) via phosphatidylinositide-3 kinase-AKT pathways [19]. However, few studies have systematically assessed the role of lncRNAs in breast and gynecologic cancers. Thus, the aim of this study was to identify promising lncRNAs as biomarkers for breast and gynecologic cancers with a literature search and data extracted from The Cancer Genome Atlas (TCGA) database and offer an overview for further studies.

Methods

Literature search and study selection

The literature searches were performed in PubMed, EMBASE and Cochrane library (up to January, 2019) for eligible studies. The search terms were shown as follows: (“lncRNA” or “Long ncRNA” or “Long Non-Translated RNA” or “Long Non-Coding RNA” or “Long Non Coding RNA” or “Long Non-Protein-Coding RNA” or “Long Non Protein Coding RNA” or “Long Non Protein Coding RNA” or “Long Non Protein Coding RNA” or “Long Non Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Intergenic Non-Protein Coding RNA” or “Long Integra...
“LincRNAs” or “LINC RNA”) AND (“Ovarian neoplasm” or “Ovarian cancer” or “Ovarian tumor” or “Ovarian tumour” or “Ovarian carcinoma” or “Ovarian malignancy” or “Endometrial neoplasm” or “Endometrial cancer” or “Endometrial tumor” or “Endometrial tumour” or “Endometrial carcinoma” or “Endometrial malignancy” or “Cervical neoplasm” or “Cervical cancer” or “Cervical tumor” or “Cervical tumour” or “Cervical carcinoma” or “Cervical malignancy” or “Breast neoplasm” or “Breast cancer” or “Breast tumor” or “Breast tumour” or “Breast carcinoma” or “Breast malignancy”). After excluding duplicates, titles and abstracts were scanned for potential eligible studies. The full articles of remaining studies were carefully reviewed to determine whether the inclusion criteria were met. In order to make the results more convincing, TCGA datasets were also applied to conduct the meta-analysis. This study was designed, conducted and reported according to PRISMA and MOOSE statements [20, 21].

The pertinent studies were selected if they meet the following criteria: (1) Studies described the association between tissue IncRNA expression level and prognosis or clinicopathological features of breast and gynecologic cancers; (2) Clinicopathological features or Hazard ratio (HR) estimates with the corresponding 95% confidence intervals (CIs) for overall survival (OS), disease-free survival (DFS) were available or could be calculated; (3) The number of the studies which reported the association between expression level of a certain IncRNA and prognosis of breast and gynecologic cancer patients must be greater than or equal to 3 (including TCGA datasets). (4) Articles were eligible for evaluation as full English papers. Reviews, letters, meeting abstracts, notes or comments were excluded. The studies concentrating on circulating IncRNAs were also excluded in our studies. Besides, to avoid overlapping data, we excluded the studies reporting the survival outcome with data extracted from TCGA database.

**Data extraction and quality assessment**

The data from each study were independently evaluated and extracted by 2 investigators (Fan Zhao and Huiqi Chen). We collected the available information from each study as follows: author, year of publication, country of origin, total number of participants, cancer types, date of inception, follow-up period, type of specimens, detection method, HR, and corresponding 95% CI. And we also extracted the data of clinicopathological parameters if available. HRs from multivariable analysis were first considered in our study due to their adjustment for confounding factors. If a study reported only Kaplan–Meier curves, the survival data were extracted with Engauge Digitizer version 10.6.

The quality assessment of each study was conducted according to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guideline [22]. The total score ranges from 0 to 20, and a higher score represents higher quality.

**Data synthesis and statistical analysis**

The primary meta-analyses were conducted to identify specific IncRNAs significantly associated with survival of patients with breast and gynecologic cancers. Chi-square and $\chi^2$ test were applied to assess the
heterogeneity among studies. P\leq0.10 and/or I^2>50\% suggests significant heterogeneity [23]. Combined HRs or ORs and 95\% CIs were calculated using the DerSimonian-Laird random-effects methods [24]. The significance of the pooled HRs or ORs were determined by Z test (p<0.05 was considered significant).

Subgroup analyses were adopted to evaluate potential modifying effect of variables and explore the source of heterogeneity in term of ethnic populations and cancer types. Funnel plots were constructed to assess the potential publication bias. All analyses were conducted using Stata software (version 12.0; StatCorp, College Station, TX, USA).

Results

Study characteristics and data quality

After searching PubMed, EMBASE and Cochrane library, a total of 3748 articles were retrieved. And 2632 articles were assessed after removing 839 duplicated records. Then, titles and abstracts were scanned, after which, 277 remaining articles entered the process of full-text reading. 165 articles were excluded for following reasons: insufficient data (n=32), foreign language (n=4), review article (n=18), meeting abstract (n=5), limited number of studies which focused on a certain IncRNA (n=108). After the above screening process, we identified 110 studies with 25 specific IncRNAs which might play an important part in the development of breast and gynecologic cancers. Afterwards, we extracted data of breast and gynecologic cancers form TCGA datasets according to the type of IncRNAs. Finally, 111 eligible studies covering 25 IncRNAs associated with survival outcome or clinicopathological features of breast and gynecologic cancer patients were included in our meta-analysis (including TCGA datasets). The process of screening was shown in Fig. S1, and the characteristics of included studies were shown in Additional file 1. The results of quality assessment were shown in Additional file 2 in accordance with REMARK guideline.

Association between specific tissue IncRNA expression and prognostic outcome in breast and gynecologic cancers

Based on literature screening, we identified 25 specific IncRNAs which might be crucial in the development of breast and gynecologic cancers. And we conducted meta-analyses which covered nearly 20000 patients to systematically evaluate the association between specific IncRNA expression and prognostic outcome of breast and gynecologic cancers, and the results were shown in Fig. 1a and b and Table 1 and Supplementary Table S3 in Additional file 3. Our analyses indicated that 3 IncRNAs (HOTAIR, GAS5, PVT1) might act as promising prognosis biomarkers for breast and gynecologic cancers, because they significantly associated with both OS and DFS for breast and gynecologic cancer patients.

More concretely, higher tissue HOTAIR expression was significantly related to poorer OS (pooled HR=1.70, 95\%CI: 1.32-2.19) and DFS (pooled HR=2.04, 95\%CI: 1.04-4.03) in breast and gynecologic cancers, as shown in Fig. S2a and S2b. Also, there was a significant association between higher tissue PVT1
expression and poorer OS (pooled HR=1.47, 95%CI: 1.17-1.86) and DFS (pooled HR=1.74, 95%CI: 1.08-2.82) in breast and gynecologic cancers (Fig. S3a and S3b). Similarly, higher tissue SPRY4-IT1, HOXA11-AS, LINP1 and SNHG15 expression might result in poorer OS and DFS in breast and gynecologic cancers (Supplementary Table S3 in Additional file 3), but this conclusion still remained unclear due to the limited study numbers.

Interestingly, 2983 patients were included to evaluate the association between tissue GAS5 expression and prognostic outcome of breast and gynecologic cancer patients, and the pooled HR was 0.51 (95%CI: 0.34-0.77) for OS and 0.40 (95%CI: 0.25-0.63) for DFS, indicating that higher tissue GAS5 expression level predicted better prognostic outcome in breast and gynecologic cancers (Fig. S4a and S4b).

In addition, there was a significant association between tissue MALAT1 (pooled HR=1.51, 95%CI: 1.09-2.08), NEAT1 (pooled HR=1.80, 95%CI: 1.25-2.58), CCAT2 (pooled HR=1.53, 95%CI: 1.09-2.14) expression and OS rather than DFS in breast and gynecologic cancers, as shown in Table 1. Nevertheless, there was a significant association between tissue UCA1 (HR=3.35, 95%CI: 1.31-8.56), CRNDE (pooled HR=11.79, 95%CI: 4.29-32.46) expression and DFS rather than OS in breast and gynecologic cancers (Table 1).

Of note, no significant association was found between tissue ANRIL, CCAT1, FEZF1-AS1 and HOTTIP expression and prognostic outcome of breast and gynecologic cancers, indicating that they might not be effective biomarkers for breast and gynecologic cancers in clinical applications (Table1). And another included IncRNAs whose study number was less than 3 were shown in Additional file 1.

**Subgroup analyses for the association between specific IncRNA expression and OS in breast and gynecologic cancers**

In order to evaluate potential modifying effect of variables and explore the source of heterogeneity, subgroup analyses were conducted according to population and cancer types, which were shown in Fig. 1a, Table 2 and Supplementary Table S4 in Additional file 3. And to make the results of subgroup analyses more convincing, the number of concluded study in each subgroup must be greater than or equal to 2.

Firstly, subgroup analyses were conducted according to population. The analyses indicated that higher tissue HOTAIR expression was significantly associated with poorer OS of breast and gynecologic cancer patients whether in an Asian population (pooled HR=2.05, 95%CI: 1.35-3.11) or in European and American populations (pooled HR=1.49, 95%CI: 1.01-2.20). However, significant association between IncRNAs and survival outcome was uniquely observed in an Asian population for PVT1 (pooled HR=2.07, 95%CI: 1.44-3.00), MALAT1 (pooled HR=2.90, 95%CI: 2.03-4.14) and CCAT2 (pooled HR=2.48, 95%CI: 1.82-3.37).

As for the cancer types, the analyses indicated that higher tissue GAS5 expression was significantly associated with better OS of both breast (pooled HR=0.42, 95%CI: 0.20-0.86) and gynecologic cancer (pooled HR=0.56, 95%CI: 0.34-0.94) patients. Besides, we proposed that higher tissue expression of
HOTAIR (pooled HR=1.98, 95% CI: 1.43-2.74), PVT1 (pooled HR = 1.45, 95% CI: 1.12-1.88) and NEAT1 (pooled HR=1.78, 95% CI: 1.15-2.78) might predicted OS of gynecologic cancer patients. Besides, MALAT1 (pooled HR=1.83, 95% CI: 1.13-2.96) expression was significantly associated with OS in breast cancer, indicating it might act as potential prognostic biomarkers for breast cancer with protective effects. And the subgroup analyses of another included lncRNAs were shown in Supplementary Table S4 in Additional file 3.

In addition, subgroup analyses suggested that heterogeneity was mainly influenced by different populations.

**Association between specific lncRNA expression and clinicopathological features in breast and gynecologic cancers**

As shown in Table 3, we also explored the association between specific lncRNA expression and clinicopathological features in breast and gynecologic cancers, such as age, FIGO stage, histology grade, lymph node metastasis (LNM), lymphovascular space invasion (LVSI) and tumor size, which might provide clues why some lncRNAs associated with survival outcome of breast and gynecologic cancers. Higher tissue expression of 10 lncRNAs was significantly associated with FIGO Stage (I-II vs III-IV) of breast and gynecologic cancers, including HOTAIR, UCA1, GAS5, ANRIL, PVT1, CCAT1, CCAT2, CRNDE, FEZF1-AS1 and HOTTIP. In addition, there was a significant association between 3 lncRNAs (ANRIL, CCAT1, FEZF1-AS1) and histology grade (G1+G2 vs G3) in breast and gynecologic cancers. And higher tissue expression of HOTAIR, UCA1, GAS5, ANRIL, CCAT1, NEAT1, CRNDE, HOTTIP was all significant associated with LNM of breast and gynecologic cancers. Besides, there was a trend that UCA1 and MALAT1 were correlated with LVSI in breast and gynecologic cancer patients. Furthermore, only CRNDE was significantly related to tumor size of patients with breast and gynecologic cancers. And the subgroup analyses of another included lncRNAs were shown in Supplementary Table S4 in Additional file 3. In general, these results indicated that different lncRNAs might function differently in clinicopathological features in breast and gynecologic cancers, which might influenced their prognostic values.

**Publication bias**

Funnel plots were shown in Fig. S5. No publication bias was found for the included studies except for the assessment of association between tissue MALAT1 expression and DFS in breast and gynecologic cancers. Nevertheless, it was still difficult to confirm whether the publication bias really existed due to the limited number of studies.

**Discussion**
Recently, accumulating evidence has demonstrated that lncRNAs performed their vital function in cancer progression and development [25]. Indeed, it was well established that lncRNA expression profile was closely related to clinically relevant cancer subtypes, suggesting its potential ability to predict tumor behavior and disease prognosis [26]. Besides, several cancer-associated lncRNAs were proved to regulate cancer invasion and metastases [27]. However, it was still controversial whether some specific lncRNAs could act as prognostic biomarkers in breast and gynecologic cancers.

In our present study, based on 111 studies and nearly 20,000 participants, we performed a meta-analysis to systematically assess the role of some specific lncRNAs in the progression of breast and gynecologic cancers and the feasibility of clinical applications of lncRNA profile. According to our study, we identified 3 lncRNAs (HOTAIR, PVT1, GAS5) significantly associated with both OS and DFS of breast and gynecologic cancer patients. Of note, the results of the subgroup analyses by ethnic populations indicated that PVT1, MALAT1 and CCAT2 were significantly associated with poorer OS in breast and gynecologic cancers in an Asian population, whereas HOTAIR had universal adaptability to predict poorer OS of breast and gynecologic cancer patients in Asian, European and American populations. Further subgroup analyses according to cancer types identified GAS5 as a protective biomarker for the survival of both breast and gynecologic cancers. Besides, 3 gynecologic specific prognostic biomarkers (including HOTAIR, PVT1 and NEAT1) and 1 breast cancer specific prognostic biomarkers (MALAT1) were also proposed according to our analyses.

Increasing number of studies focused on the prognostic value of HOTAIR in breast and gynecologic cancers. Consistent with our findings, HOTAIR expression has been proposed to be related to cancer cell migration and invasiveness [28, 29], which was the key factor for the progression and development of breast and gynecologic cancers. Some studies provided possible mechanisms for higher HOTAIR expression as a negative prognostic factor in breast and gynecologic cancers. It was known that overexpression of HOTAIR was able to stimulate ER signaling, which led to tamoxifen resistance and tumor progression in breast cancer [30]. Besides, HOTAIR could indirectly inhibit miR-7 which reversed the EMT program of breast cancer stem cells by down-regulating the STAT3 signaling pathway [31]. It was also reported that HOTAIR could act as a sponge of miR-206 and regulate CCND1 and CCND2 expression in ovarian cancer [29].

Similarly, PVT1 was also a promising prognostic biomarker for breast and gynecologic under our analyses. Specifically, PVT1 played an essential role in tumor cell proliferation and growth by regulating KLF5/β-catenin signaling pathway in breast cancer [32]. Consistently, PVT1 knockdown inhibited cell proliferation and promoted apoptosis in breast and ovarian cancer cell lines [33]. It was noteworthy that PVT1/miR-195 axis could regulate the response of cervical cancer cells to paclitaxel [34].

Furthermore, our studies proposed the potential value for SPRY4-IT1, HOXA11-AS, SNHG15, TP73-AS1 to predict poorer survival outcome, but the reliability of the conclusion was limited due to the numbers of included studies. For example, the exact mechanism for SPRY4-IT1 and HOXA11-AS to play oncogenic roles was still unclear. SPRY4-IT1 was demonstrated to be upregulated in breast cancer tissues and suppress proliferation and increase apoptosis of breast cancer cell through targeting ZNF703 [35]. SPRY4-
IT1 knockdown might inhibit the proliferation and arrest cell cycle at G0/G1 stage in ovarian cancer cells [36]. And it was shown that HOXA11-AS could increase cell proliferation, invasion and metastasis of breast cancer in vivo and in vitro experiments through regulating EMT program [37]. In general, more studies of high quality were needed to confirm their prognostic value.

Unlike the lncRNAs mentioned above, our study showed higher tissue GAS5 expression might predict better prognosis in breast and gynecologic cancers. Overexpression of GAS5 might enhance the sensitivity of cervical cells to cisplatin through miR-21 by regulating the level of PTEN and the phosphorylation of Akt, thus inhibiting cancer cell migration and invasion [38]. Another study demonstrated that GAS5 could act as a ceRNA for miR-196a-5p, which regulated FOXO1 expression and downstream PI3K/Akt phosphorylation and then promoted the progression of triple-negative breast cancer [39]. Consistently, our study noted that higher tissue GAS5 expression inversely associated with lymph node metastasis in breast and gynecologic cancers, which partly explained its capacity as a prognostic biomarker.

Our studies had some strengths. To our knowledge, it was the first study to systematically evaluate the prognostic value of lncRNA profile in breast and gynecologic cancers. Of note, the study was performed through literature search and data extracted from TCGA database, which contributed to the reliability of the results. In addition, we offered some information about the association between specific IncRNA expression and clinicopathological features in breast and gynecologic cancers, which explain partly the prognostic value of some specific IncRNAs. Finally, the methods of this studies were rigorous and in accordance with guidelines for conducting a meta-analysis.

However, there were also some limitations in the current study. Firstly, though subgroup analyses were conducted, the heterogeneity of the studies for some IncRNA analyses could not be fully explained. Besides, due to the limited number of studies, we could not conduct subgroup analyses for some IncRNAs, thus it was difficult for us to explore the potential modifying effect of ethnic populations and cancer types for some IncRNAs, which increased restrictions on our conclusions. What’s more, the criterion of high expression of IncRNAs was not consistent among the included studies. And limited data made it impossible for us to analyze the impact of co-expression of several IncRNAs on the prognostic outcome in breast and gynecologic cancers. Therefore, further high-quality and well-designed studies are warranted to confirm our current findings.

Conclusions

The current study demonstrated that tissue IncRNA expression might associated with survival outcome of breast and gynecologic cancers patients and specific IncRNAs could act as prognostic biomarkers of breast and gynecologic cancers, especially for HOTAIR, PVT1 as poorer prognostic biomarkers and GAS5 as a positive prognostic biomarker.

Abbreviations
IncRNAs: Long non-coding RNAs; OS: Overall survival; DFS: Disease-free survival; EOC: epithelial ovarian cancer; EMT: Epithelial-mesenchymal transition; TCGA: The Cancer Genome Atlas; HR: Hazard ratio; OR: Odds ratio; CI: Confidence intervals; REMARK: Recommendations for Tumor Marker Prognostic Studies guideline;LNM: lymph node metastasis; LVSi: Lymphovascular space invasion

Declarations

Acknowledgements

Not applicable.

Authors’ Contributions

YW and DX contributed to conception and design of the study, and had the right to grant on behalf of all authors; FZ, HC and KC contributed to design of the study, data acquisition, analysis and interpretation of the data and drafting the manuscript; DY and SW extracted and analyzed data from TCGA database and provided support of bioinformatics analysis; HZ and WL provided valuable suggestions and polished the manuscript. All authors read and approved the final manuscript.

Funding

This work was funded by Zhejiang Provincial Natural Science Foundation of China (Grant No. LY18C060001) and National Natural Science Foundation of China (Grant No: 31471297, 81773016). The funders had no role in the study design, collection, analysis, and interpretation of data.

Availability of data and materials

The data supporting the conclusions of this article are included in the article and its supplementary information files.

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr. 2013.

2. Jensen A, Sharif H, Olsen JH, Kjaer SK: Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American journal of epidemiology 2008, 168(1):49-57.

3. Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL et al: Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nature communications 2018, 9(1):4904.

4. Weigelt B, Peterse JL, van ‘t Veer LJ: Breast cancer metastasis: markers and models. Nature reviews Cancer 2005, 5(8):591-602.

5. Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL: Metastatic gynecologic malignancies: advances in treatment and management. Clinical & experimental metastasis 2018, 35(5-6):521-533.

6. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science (New York, NY) 2004, 306(5696):636-640.

7. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE et al: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447(7146):799-816.

8. Wapinski O, Chang HY: Long noncoding RNAs and human disease. Trends in cell biology 2011, 21(6):354-361.

9. Guttmann M, Rinn JL: Modular regulatory principles of large non-coding RNAs. Nature 2012, 482(7385):339-346.

10. Batista PJ, Chang HY: Long noncoding RNAs: cellular address codes in development and disease. Cell 2013, 152(6):1298-1307.

11. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S et al: The landscape of long noncoding RNAs in the human transcriptome. Nature genetics 2015, 47(3):199-208.

12. Perez DS, Hoage TR, Pritchett JR, Ducharme-Smith AL, Halling ML, Ganapathiraju SC, Streng PS, Smith DI: Long, abundantly expressed non-coding transcripts are altered in cancer. Human molecular genetics 2008, 17(5):642-655.

13. Tsai MC, Spitale RC, Chang HY: Long intergenic noncoding RNAs: new links in cancer progression. Cancer research 2011, 71(1):3-7.

14. Weidle UH, Birzele F, Kollmorgen G, Ruger R: Long Non-coding RNAs and their Role in Metastasis. Cancer genomics & proteomics 2017, 14(3):143-160.

15. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464(7291):1071-1076.
16. Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G et al: Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast cancer research and treatment 2012, 136(3):875-883.

17. Zhang J, Lin Z, Gao Y, Yao T: Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. Journal of experimental & clinical cancer research : CR 2017, 36(1):5.

18. Cao Y, Shi H, Ren F, Jia Y, Zhang R: Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Experimental cell research 2017, 359(1):185-194.

19. Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, Gao S, You Z, Zhan C, Liu F et al: Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. International journal of clinical and experimental pathology 2015, 8(5):4881-4891.

20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000, 283(15):2008-2012.

21. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009, 6(7):e1000097.

22. Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS medicine 2012, 9(5):e1001216.

23. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002, 21(11):1539-1558.

24. DerSimonian R, Laird N: Meta-analysis in clinical trials. Controlled Clinical Trials 1986, 7(3):177-188.

25. Schmitt AM, Chang HY: Long Noncoding RNAs in Cancer Pathways. Cancer Cell 2016, 29(4):452-463.

26. Du Z, Fei T, Verhaak RG, Su Z, Zhang Y, Brown M, Chen Y, Liu XS: Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nature structural & molecular biology 2013, 20(7):908-913.

27. Huarte M: The emerging role of IncRNAs in cancer. Nature Medicine 2015, 21:1253.

28. Zhou M, Zhang Z, Zhao H, Bao S, Sun J: A novel IncRNA-focus expression signature for survival prediction in endometrial carcinoma. BMC cancer 2018, 18(1):39.

29. Chang L, Guo R, Yuan Z, Shi H, Zhang D: LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018, 49(4):1289-1303.

30. Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC, Yu J: LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 2016, 35(21):2746-2755.

31. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y, Dou J: MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem cells (Dayton, Ohio) 2014, 32(11):2858-2868.
32. Tang J, Li Y, Sang Y, Yu B, Lv D, Zhang W, Feng H: LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling. Oncogene 2018, 37(34):4723-4734.

33. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL et al: Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2007, 13(19):5745-5755.

34. Shen CJ, Cheng YM, Wang CL: LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. Journal of drug targeting 2017, 25(7):637-644.

35. Shi Y, Li J, Liu Y, Ding J, Fan Y, Tian Y, Wang L, Lian Y, Wang K, Shu Y: The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Molecular cancer 2015, 14.

36. Yan C, Jiang Y, Wan Y, Zhang L, Liu J, Zhou S, Cheng W: Long noncoding RNA NBAT-1 suppresses tumorigenesis and predicts favorable prognosis in ovarian cancer. OncoTargets and therapy 2017, 10:1993-2002.

37. Zhou J, Cao S, Li W, Wei D, Wang Z, Li G, Pan X, Lei D: Time-course differential IncRNA and mRNA expressions in radioresistant hypopharyngeal cancer cells. Oncotarget 2017, 8(25):40994-41010.

38. Wen Q, Liu Y, Lyu H, Xu X, Wu Q, Liu N, Yin Q, Li J, Sheng X: Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2017, 27(6):1096-1108.

39. Li S, Zhou J, Wang Z, Wang P, Gao X, Wang Y: Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018, 104:451-457.

Tables
Table 1

Meta-analysis of the association between tissue lncRNA expression and survival outcome in breast and gynecologic cancers.

| lncRNA | Study number | No. of participants | Pooled HR (95% CI) |
|--------|--------------|---------------------|--------------------|
|        |              |                     | OS     | DFS     |
| HOTAIR | 14           | 3672                | 1.70(1.32–2.19)* | 2.04(1.04–4.03)* |
| UCA1   | 6            | 2647                | 1.34(0.98–1.82)  | 3.35(1.31–8.56)* |
| GAS5   | 8            | 2983                | 0.51(0.34–0.77)* | 0.40(0.25–0.63)* |
| ANRIL  | 5            | 2578                | 1.32(0.97–1.79)  | -                  |
| PVT1   | 9            | 3281                | 1.47(1.17–1.86)* | 1.74(1.08–2.82)* |
| MALAT1 | 10           | 9892                | 1.51(1.09–2.08)* | 1.11(0.58–2.12)   |
| CCAT1  | 4            | 2576                | 1.21(0.85–1.73)  | 2.01(0.72–5.62)   |
| NEAT1  | 6            | 2789                | 1.80(1.25–2.58)* | -                  |
| CCAT2  | 5            | 2817                | 1.53(1.09–2.14)* | 1.78(0.97–3.27)   |
| CRNDE  | 4            | 2587                | 1.08(0.69–1.69)  | 11.79(4.29–32.46)*|
| FEZF1-AS1 | 4         | 2216                | 1.42(0.88–2.31)  | -                  |
| HOTTIP | 4            | 1987                | 1.62(1.00–2.61)  | -                  |

-Could not be calculated.

*Significant association was indicated, statistical z test: P<0.05.

HR, hazard risk; CI, confidence interval.
Table 2

Subgroup analyses for the association between tissue IncRNA expression and OS in breast and gynecologic cancers.

| Categories | IncRNA | Classification | Study number | No. of participants | HR (95% CI) | Heterogeneity |
|------------|--------|----------------|--------------|---------------------|-------------|---------------|
|            |        |                |              |                     |             | I²            |
| Population | HOTAIR | Asian population | 8            | 630                 | 2.05(1.35–3.11)* | 71.20% | 0.001 |
|            |        | European and American populations | 5            | 2878                | 1.49(1.01–2.20)* | 78.20% | 0.000 |
|            | PVT1   | Asian population | 3            | 284                 | 2.07(1.44–3.00)* | 67.30% | 0.009 |
|            |        | European and American populations | 3            | 2568                | 1.10(0.91–1.33) | 46.60% | 0.095 |
|            | MALAT1 | Asian population | 4            | 297                 | 2.90(2.03–4.14)* | 0.00% | 0.869 |
|            |        | European and American populations | 2            | 2827                | 1.06(0.84–1.35) | 58.30% | 0.048 |
|            | CCAT2  | Asian population | 3            | 352                 | 2.48(1.82–3.37)* | 0.00% | 0.734 |
|            |        | European and American populations | 2            | 2465                | 1.08(0.92–1.27) | 0.00% | 0.509 |
|            | CRNDE  | Asian population | 2            | 166                 | 0.86(0.19–3.84) | 92.90% | 0.000 |
|            |        | European and American populations | 2            | 2524                | 1.15(0.71–1.87) | 80.30% | 0.000 |
| Cancer type| HOTAIR | gynecologic cancer | 9            | 1895                | 1.98(1.43–2.74)* | 65.20% | 0.002 |
|            |        | breast cancer | 5            | 1613                | 1.26(0.84–1.91) | 76.20% | 0.002 |
|            | UCA1   | gynecologic cancer | 4            | 1438                | 1.32(0.97–1.80) | 51.40% | 0.067 |

*Significant association was indicated, statistical z test: P<0.05.
| Non-coding RNA | Disease Type       | Samples | Patients | Hazard Ratio (95% CI) | AUC     | P Value |
|----------------|--------------------|---------|----------|-----------------------|---------|---------|
| GAS5           | Gynecologic cancer | 5       | 1631     | 0.56 (0.34–0.94)*     | 86.10%  | 0.000   |
|                | Breast cancer      | 4       | 1352     | 0.42 (0.20–0.86)*     | 82.70%  | 0.001   |
| ANRIL          | Gynecologic cancer | 4       | 1446     | 1.39 (0.96–2.01)      | 72.00%  | 0.003   |
|                | Breast cancer      | 2       | 1132     | 1.22 (0.51–2.93)      | 73.80%  | 0.051   |
| PVT1           | Gynecologic cancer | 7       | 1992     | 1.45 (1.12–1.88)*     | 73.60%  | 0.000   |
|                | Breast cancer      | 3       | 1289     | 1.58 (0.79–3.14)      | 85.20%  | 0.001   |
| MALAT1         | Gynecologic cancer | 3       | 1391     | 1.31 (0.84–2.04)      | 79.10%  | 0.001   |
|                | Breast cancer      | 4       | 1733     | 1.83 (1.13–2.96)*     | 75.10%  | 0.007   |
| CCAT1          | Gynecologic cancer | 2       | 1295     | 1.15 (0.82–1.62)      | 55.50%  | 0.080   |
|                | Breast cancer      | 2       | 1187     | 1.41 (0.37–5.33)      | 91.30%  | 0.001   |
| NEAT1          | Gynecologic cancer | 4       | 1506     | 1.78 (1.15–2.78)*     | 82.10%  | 0.000   |
|                | Breast cancer      | 3       | 1283     | 1.87 (0.82–4.26)      | 89.50%  | 0.000   |
| CRNDE          | Gynecologic cancer | 3       | 1492     | 1.01 (0.57–1.78)      | 83.40%  | 0.000   |
|                | Breast cancer      | 2       | 1198     | 1.37 (0.84–2.26)      | 53.50%  | 0.142   |
| FEZF1-AS1      | Gynecologic cancer | 3       | 1091     | 1.46 (0.69–3.10)      | 83.50%  | 0.000   |
|                | Breast cancer      | 2       | 1125     | 1.30 (0.90–1.89)      | 0.00%   | 0.376   |

*Significant association was indicated, statistical z test: P<0.05.
Table 3

The association between tissue lncRNA expression and clinicopathological features in breast and gynecologic cancers.

| Pooled OR (95%CI) | Age      | FIGO Stage (I-II vs III-IV) | Histology Grade (G1 + G2 vs G3) | Lymph node metastasis (LNM) | Lymphovascular space invasion (LVSI) | Tumor size       |
|------------------|----------|-----------------------------|---------------------------------|-----------------------------|--------------------------------------|------------------|
| lncRNAs          |          |                             |                                 |                             |                                      |                  |
| HOTAIR           | 1.10(0.79–1.53) | 2.41(1.17–4.94)*       | 1.45(0.87–2.39)                | 8.18(4.87–13.74)*            | 1.43(0.70–2.93)                   | 1.01(0.25–3.99)  |
| UCA1             | 1.03(0.59–1.80) | 2.88(1.60–5.17)*         | 1.24(0.50–3.10)                | 3.70(1.98–6.91)*             | 4.38(1.08–17.68)*                  | 1.19(0.34–4.18)  |
| GAS5             | 0.96(0.70–1.33) | 0.15(0.08–0.31)*         | 0.81(0.57–1.14)                | 0.18(0.07–0.48)              | 1.40(0.76–2.59)                   | 0.60(0.21–1.70)  |
| ANRIL            | 0.77(0.46–1.27) | 5.43(2.57–11.45)*        | 2.23(1.24–4.00)                | 3.42(1.29–9.04)*             |                                      | 2.31(0.98–5.44)  |
| PVT1             | 0.95(0.67–1.36) | 4.02(2.27–7.13)*         | 1.37(0.72–2.63)                | 0.90(0.35–2.30)              |                                      | 0.93(0.35–2.48)  |
| MALAT1           | 1.25(0.96–1.63) | 10.91(0.49–245.45)       | 0.97(0.44–2.13)                | 1.86(0.58–5.95)              | 3.33(1.43–7.75)*                   | 0.73(0.36–1.46)  |
| CCAT1            | 0.88(0.47–1.64) | 38.50(9.31–159.16)*      | 4.19(1.56–11.23)*              | 10.59(3.65–30.73)*           |                                      | 1.34(0.56–3.21)  |
| NEAT1            | 0.93(0.66–1.31) | 1.66(0.40–6.84)          | 2.21(0.42–11.70)               | 3.11(0.59–16.52)             |                                      | 0.84(0.41–1.71)  |
| CCAT2            | 0.77(0.51–1.16) | 3.40(1.93–6.00)*         | 0.92(0.56–1.53)                | 1.76(0.32–9.54)              |                                      | 0.77(0.46–1.29)  |
| CRNDE            | 0.71(0.37–1.35) | 3.02(1.08–8.44)*         | 2.08(0.79–5.50)                | 13.29(3.89–45.41)*           |                                      | 2.68(1.42–5.07)* |
| FEZF1-AS1        | 1.16(0.68–1.97) | 2.73(1.48–5.04)*         | 2.32(1.30–4.15)*               |                                 |                                      | 0.93(0.53–1.64)  |

*Could not be calculated.

*Significant association was indicated, statistical z test: P < 0.05.

The analysis of FIGO stage only included studies focusing on gynecologic cancers.

OR: odds ratio.
| Pooled OR | Age | FIGO Stage (I-IV vs III-IV) | Histology Grade (G1 + G2 vs G3) | Lymph node metastasis (LNM) | Lymphovascular space invasion (LVSI) | Tumor size |
|----------|-----|-----------------------------|---------------------------------|-----------------------------|--------------------------------------|------------|
| HOTTIP   | 1.23 (0.72–2.12) | 0.22 (0.08–0.60)* | 1.34 (0.52–3.46) | 0.32 (0.18–0.59)* | - | 1.43 (0.16–12.51) |

*Could not be calculated.

*Significant association was indicated, statistical z test: P < 0.05.

The analysis of FIGO stage only included studies focusing on gynecologic cancers.

OR: odds ratio.

---

**Supplemental**

**Supplementary tables**

Table S1. Characteristics of the included studies.

Table S2. Quality assessment performed according to the REMARK guideline.

Table S3. Meta-analysis of the association between tissue lncRNA expression and survival outcome in breast and gynecologic cancers (The number of included studies was less than or equal to 3).

Table S4. Subgroup analyses for the association between tissue lncRNA expression and OS in breast and gynecologic cancers (The number of included studies was less than or equal to 3).

Table S5. The association between tissue lncRNA expression and clinicopathological features in breast and gynecologic cancers (The number of included studies was less than or equal to 3).

**Supplementary figure legends**

Fig. S1. Flow diagram of study selection process.

Fig. S2. Association between tissue HOTAIR expression and survival of breast and gynecologic cancers. a Forest plots of the association between tissue HOTAIR expression and OS in breast and gynecologic cancers. b Forest plots of the association between tissue HOTAIR expression and DFS in breast and gynecologic cancers.
Fig. S3. Association between tissue PVT1 expression and survival of breast and gynecologic cancers. a Forest plots of the association between tissue PVT1 expression and OS in breast and gynecologic cancers. b Forest plots of the association between tissue PVT1 expression and DFS in breast and gynecologic cancers.

Fig. S4. Association between tissue GAS5 expression and survival of breast and gynecologic cancers. a Forest plots of the association between tissue GAS5 expression and OS in breast and gynecologic cancers. b Forest plots of the association between tissue GAS5 expression and DFS in breast and gynecologic cancers.

Fig. S5. Funnel plots for the association between tissue lncRNA expression and survival outcome of breast and gynecologic patients in the current study.